1.
POSITION BRIEF
INDEPENDENT CHAIR & INDEPENDENT DIRECTOR
HONEYLAB LIMITED
Purpose and context
HoneyLab is a New Zealand research-based pharmaceutical company, specializing in high-value
Over The Counter (OTC) treatments derived from bees and their environment. Its primary focus is on
hard to treat conditions in the topical dermatology, topical pain management and nutrition based
segments. The company develops pharmaceutical class IP protection and conducts full scale Phase 2
and Phase 3 clinical studies to prove efficacy. Its key products are market ready for commercialisation
through licensing and distribution. HoneyLab has identified an enormous untapped market in the non
prescription consumer healthcare space - it’s an incredibly exciting venture to be involved in.
The executive team includes Dr Shaun Holt (Research & Development), Laurence Greig (Business
and Commercial) and Alan Barrett (Supply Chain). They sit on the board alongside two non executive
directors, one of whom (the Chair) is retiring. The medium term plan is to reduce the number of
executives on the board and rebalance this with a majority of independent directors.
Honeylab’s current priorities are to commercialise its protected IP through two licensing deals, capital
raise and to continue its strategy of being an IP (rather than product or brand) led business. The new
board will support these priorities by bringing further credibility to the company and ensure there is
clearer separation between governance and management responsibilities/discussions. Other areas of
focus for the business are the development of back office processes/systems and the continuation of
investment in one major phase 3 trial each year.
This opportunity would be attractive to individuals who are excited by the tremendous research results
to date and the growth potential, thrive on the intellectual challenge of creating value through IP
(rather than brand) and align with the social good/health benefit aspect of HoneyLab.
For more information on the company, please visit http://www.honeylab.co.nz/
Person Specification
Our Chair appointee will currently be an experienced Chair or seasoned director, confident governing
in an environment with multiple stakeholders.
Further background and experience we are seeking between the two appointees is:
• A track record in negotiating licence agreements with strong understanding of the legal
technicalities that underpin these agreements
• Capital raising experience and broader finance/treasury knowledge
• Experienced in the workings and machinations of central government and related agencies
While not mandatory, any experience within the biotech or pharmaceutical industries would be
advantageous.
The personal traits of our successful board members will include:

2.
• An affinity with entrepreneurs and the nature of fast growing / agile environments
• Ability to keep the board and company focussed on its strategy
• A lateral thinker, stimulated by HoneyLab’s non traditional IP based business model
• Confidence in themslves to ask questions they don’t know the answer to
• Desire and ability to mentor senior executives and/or other board members
The role is open to individuals living throughout New Zealand.
Time commitment and term
Board meetings will be held six times per year, accompanied by two strategy days and some minor
sub committee work. Outside of the board meetings independent directors are expected to mentor
senior executives, make introductions to the company and support the executive team at key external
meetings.
We anticipate the role starting late July 2015 for an initial term of two years.
Remuneration
The fee for the Chair will be $45,000pa and $30,000pa for the independent director. D&O insurance is
in place for all directors.
To Apply
For further information on the role please contact the company’s adviser, Simon Telfer, via
simon@stimulusnz.com or on +64 21 321 901.
To express interest in the role please visit www.appointbetterboards.co.nz/APT5309 (brief
registration required).
The closing date for applications is 5.00pm on 29 May 2015.